MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-1
Clinical trials for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-1 explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-1 trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapies aim to beat High-Risk blood cancers
Disease control OngoingThis study tests whether adding another drug (lenalidomide or vorinostat) to the standard chemotherapy azacitidine works better than azacitidine alone for people with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). About 282 adults took part…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-1
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:36 UTC
-
New antibody takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-phase study tests a new antibody called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The main goal is to find a safe dose and check for side effects. Researchers hope the antibody can slow or stop cancer growth.
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-1
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:09 UTC